Hims & Hers Health (HIMS) Dropped, So What Is Driving Attention Now?

October 17, 2026 - 15:20

Hims & Hers Health (HIMS) is back in focus after fresh product news, with Hers Hair now rolling out in the UK as a clinician-led subscription hair loss service for women. The move extends the company's reach beyond the US and targets a market where demand for accessible treatment continues to grow.

Recent price action tells a mixed story for Hims & Hers Health. The share price is down 4.46% over the last day and 9.22% over the past week, yet roughly flat over one month and weaker year to date. The 1-year total shareholder return has declined 43.61%, while the 3-year total shareholder return remains very large, reflecting how far the stock has traveled since its early trading days.

The UK launch matters because it tests whether the subscription model that worked in the US can travel. Hers Hair combines clinician oversight with ongoing treatment, which fits the company's broader push into personalized care. Investors will watch uptake closely, since international expansion carries regulatory and marketing costs that can weigh on margins before revenue scales.

For now, the stock sits between a weak short-term trend and a long-term record that still looks strong. The next signal will come from how quickly the new service gains subscribers and whether that momentum supports the wider business.